CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting
Monogram Health Welcomes Casey McKeon to Executive Leadership Team
EVERSANA INTOUCH Wins Five Clio Awards
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
America’s Best Wings: Everything You Need to Know
“We want the look at home hospitalization to change”
In Abidjan, to poor men, impossible love
Kidney transplant: AI to correct erroneous rejection diagnoses
Why do I need to get rid of dental plaque?
The Prévifrance mutual insurance company shows its good health and continues to conquer policyholders
At 16-months median follow-up, CARVYKTI® significantly improved progression-free survival compared to two standard treatments1 Data presented at the 2023 ASCO and EHA Annual Meetings and published...